Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Allergy UK

- PMLiVE

LEO Pharma and Allergy UK launch ‘Don’t Ignore’ chronic hand eczema campaign

The campaign aims to improve awareness and understanding of the condition

- PMLiVE

LEO Pharma to acquire Replay gene therapy platform

The acquisition will advance innovation for patients with rare skin diseases

- PMLiVE

Matt Ferriday announced as General Manager for LEO Pharma UK

Ferriday most recently held senior leadership roles at Ipsen Biopharma

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

- PMLiVE

LEO Pharma receives NICE approval for chronic hand eczema cream

The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

- PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

The cream is now the first treatment approved by the regulator specifically for this patient population

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

LEO Pharma and the Parker Institute join forces to advance dermatology research

The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

There is currently no cure for the group of rare inherited skin disorders

- PMLiVE

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links